SCHEMBL1928940

SCHEMBL1928940

CC(C)C(O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP2D6 P10635 1/20 0.37
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
KMT2A Q03164 2/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
PTGS2 P35354 1/20 0.35
PTGS1 P23219 1/20 0.33
ALOX5 P09917 1/20 0.33
SRC P12931 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
PKM P14618 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10154532 1.00 ATM (0.37) ATML3MBTL1CYP2D6PPARGPPARA
SCHEMBL4188849 0.92 CYP2D6 (0.41) ATML3MBTL1CYP2D6KMT2ATP53
SCHEMBL1926988 0.83 KMT2A (0.41) ATML3MBTL1CYP2D6KMT2APTGS2
SCHEMBL1487233 0.83 KMT2A (0.41) ATML3MBTL1CYP2D6KMT2APTGS2
SCHEMBL1927300 0.83 KMT2A (0.41) ATML3MBTL1CYP2D6KMT2APTGS2
SCHEMBL4180791 0.83 KMT2A (0.47) ATML3MBTL1CYP2D6KMT2ATSHR
SCHEMBL7572490 0.83 KMT2A (0.47) ATML3MBTL1CYP2D6KMT2ATSHR
SCHEMBL5873085 0.81 PTGS2 (0.35) ATML3MBTL1CYP2D6KMT2APTGS2
SCHEMBL8892064 0.81 PTGS2 (0.35) ATML3MBTL1CYP2D6KMT2APTGS2
SCHEMBL29525590 0.78 ALOX5 (0.38) CYP2D6KMT2APTGS2ALOX5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180334441-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2018-11-22 US disclosed
US-10017482-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2018-07-10 US disclosed
US-20170066733-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2017-03-09 US disclosed
US-9499503-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2016-11-22 US disclosed
US-9102639-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2015-08-11 US disclosed
US-20150210658-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2015-07-30 US disclosed
CN-103951633-A Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC 2014-07-30 CN disclosed
CN-103626720-A Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC 2014-03-12 CN disclosed
US-8623895-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2014-01-07 US disclosed
US-20120270803-A1 Mitotic Kinesin Inhibitors and Methods of Use Thereof ARRAY BIOPHARMA, INC. 2012-10-25 US disclosed
US-8236825-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2012-08-07 US disclosed
EP-1809280-B1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2011-09-07 EP disclosed
US-20110201651-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. 2011-08-18 US disclosed
US-7956073-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2011-06-07 US disclosed
US-7449486-B2 Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders ARRAY BIOPHARMA INC. (US) 2008-11-11 US disclosed
US-20080182992-A1 Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents ARRAY BIOPHARMA, INC. 2008-07-31 US disclosed
EP-1809280-A2 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2007-07-25 EP disclosed
US-20060100161-A1 Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders ARRAY BIOPHARMA INC. 2006-05-11 US disclosed
WO-2006044825-A2 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201651-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 ATM 602/4885L3MBTL1 3042/4885CYP2D6 4587/4885
US-20150210658-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 ATM 602/4885L3MBTL1 3042/4885CYP2D6 4587/4885
US-20080182992-A1 Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents KIF5B, KIF2C, KIFC1 ATM 1721/4885L3MBTL1 4125/4885CYP2D6 4582/4885
US-20180334441-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF18B, KIF18A ATM 1001/4885L3MBTL1 2309/4885CYP2D6 4662/4885
US-20060100161-A1 Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders KIF5B, KIF2C, KIFC1 ATM 2035/4885L3MBTL1 3641/4885CYP2D6 4160/4885
US-10017482-B2 Mitotic kinesin inhibitors and methods of use thereof KIF5B, KIF18B, KIF18A ATM 1001/4885L3MBTL1 2309/4885CYP2D6 4662/4885
US-20120270803-A1 Mitotic Kinesin Inhibitors and Methods of Use Thereof KIF5B, KIF2C, KIFC1 ATM 602/4885L3MBTL1 3042/4885CYP2D6 4587/4885
US-20170066733-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF18B, KIF18A ATM 1001/4885L3MBTL1 2309/4885CYP2D6 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.